Short-term effect of anti-TNF-α therapy on nitric oxide production in patients with severe rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 27, Issue 3, 2009, Pages 452-458

  Gonzalez Gay, Miguel A ^a   Garcia Unzueta, Maria T ^b   Berja, Ana ^b   Vazquez Rodriguez, Tomas R ^a   Miranda Filloy, Jose A ^a   Gonzalez Juanatey, Carlos ^a   De Matias, Jose M ^a   Martin, Javier ^c   Dessein, Patrick H ^d   Llorca, Javier ^e  

^a HOSPITAL XERAL CALDE   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c CSIC   (Spain)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Anti TNF antibody infliximab; Cardiovascular morbidity; Inflammation; Nitric oxide; Rheumatoid arthritis

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHLOROQUINE; DICLOFENAC; ENALAPRIL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GHRELIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 3; LEPTIN; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; NAPROXEN; NITRATE; NITRIC OXIDE; NITRITE; NITROUS OXIDE; PADGEM PROTEIN; PREDNISONE; RESISTIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; MORNING DOSAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NITRATES; NITRIC OXIDE; NITRITES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67651177802     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. GONZALEZ-GAYMA, GONZALEZ-JUANATEY C, MARTIN J: Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005; 35: 8-17. (Pubitemid 41111466)
2. SERIOLO B, PAOLINO S, FERRONE C et al.: Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis. Clin Rheumatol 2007; 26: 1799-1800
3. GONZALEZ-GAY MA, DE MATIAS JM, GONZALEZ-JUANATEY C et al.: Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 83-86
4. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, ANA BERJA et al.: Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1644-1646
5. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, GONZALEZ-JUANATEY C et al.: Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 311-316 (Pubitemid 351659139)
6. GONZALEZ-JUANATEY C, TESTA A, GARCIA-CASTELO A et al.: Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004; 51: 447-450
7. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, DE MATIAS JM et al.: Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 373-379
8. LUNDBERG JO, WEITZBERG E: NO generation from nitrite and its role in vascular control. Arterioscler Thromb Vasc Biol 2005; 25: 915-922
9. GONZALEZ-GAY MA, LLORCA J, SANCHEZ E et al.: Inducible but not endothelial nitric oxide synthase polymorphism is associated with susceptibility to rheumatoid arthritis in northwest Spain. Rheumatology (Oxford) 2004; 43: 1182-1185
10. DESSEIN PH, GONZALEZ-GAY MA, WOODIWISS AJ et al.: The impact of the metabolic syndrome on cardiovascular risk and disease in rheumatoid arthritis. Future Rheumatology 2008; 3: 335-349
11. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatology Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324
12. GONZALEZ-GAY MA, GARCIA-PORRUA C, GUERRERO J et al.: The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 2003; 49: 388-393
13. GONZALEZ-GAYMA, GONZALEZ-JUANATEY C, LOPEZ-DIAZ MJ et al.: HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 125-132
14. GONZALEZ-GAY MA, LLORCA J, GARCIA-UNZUETA MT et al.: High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 596-603.
15. GONZALEZ-JUANATEY C, LLORCA J, GARCIA-PORRUA C et al.: Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum 2006; 55: 150-153
16. GONZALEZ-JUANATEY C, LLORCA J, SANCHEZ-ANDRADE A et al.: Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 2006; 24: 309-312 (Pubitemid 44151152)
17. VAN GESTEL AM, STUCKI G: Evaluation of established rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 1999; 13: 629-644
18. VIS M, NURMOHAMED MT, WOLBINK G et al.: Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 252-255
19. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, BERJA A et al.: Anti-TNF-α therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin Exp Rheumatol 2009; 27: 222-228
20. MIERAU M, SCHOELS M, GONDA G et al.: Assessing remission in clinical practice. Rheumatology 2007; 46: 975-979
21. CONNELLY L, PALACIOS-CALLENDER M, AMEIXA C et al.: Biphasic regulation of NF-kappa B activity underlies the pro- and anti-inflammatory actions of nitric oxide. J Immunol 2001; 166: 3873-3881
22. HÜRLIMANN D, FORSTER A, NOLL G et al.: Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-2187
23. SATTAR N, MCCAREY DW, CAPELL H et al.: Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-2963
24. SCHUGER L, VARANI J, MARKS RM et al.: Cytotoxicity of tumor necrosis factor-alpha for human umbilical vein endothelial cells. Lab Invest 1989; 61: 62-68 (Pubitemid 19203854)
25. XIA Y, ZWEIER JL: Direct measurement of nitric oxide generation from nitric oxide synthase. Proc Natl Acad Sci USA 1997; 94: 12705-12710 (Pubitemid 27492593)
26. BLACKWELL TS, CHRISTMAN JW: The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 1997; 17: 3-9. (Pubitemid 127500814)
27. COLLINS T, READ MA, NEISH AS et al.: Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 1995; 9: 899-909.
28. CARMONA L, DESCALZO MA, PEREZ-PAMPIN E et al.: All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007; 66: 880-885
29. MASTRONARDI CA, YU WH, MCCANN SM: Resting and circadian release of nitric oxide is controlled by leptin in male rats. Proc Natl Acad Sci USA 2002; 99: 5721-5726
30. RODRÍGUEZ A, FORTUÑO A, GÓMEZ-AMBROSI J et al.: The inhibitory effect of leptin on angiotensin II-induced vasoconstriction in vascular smooth muscle cells is mediated via a nitric oxide-dependent mechanism. Endocrinology 2007; 148: 324-331
31. REDDY SV, WANCHU A, KHULLAR M et al.: Leflunomide reduces nitric oxide production in patients with active rheumatoid arthritis. Int Immunopharmacol 2005; 5: 1085-1090 (Pubitemid 40501753)